Neonatal sepsis: A challenge in hemostaseology

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 6, 1999, Pages 531-536

  Kreuz, Wolfhart ^a   Veldmann, Alex ^a   Fischer, Doris ^a   Schlösser, Rolf ^a   Werner Rettwitz, Volk ^a   Ettingshausen, Carmen Escuriola ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antithrombin; Infants; Neonates; Plasminogen activator inhibitor 1; Protein C; Sepsis

Indexed keywords

ALTEPLASE; ANTITHROMBIN; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12A; COMPLEMENT COMPONENT C1S INHIBITOR; HEPARIN; KALLIKREIN; PROTEIN C; STREPTOKINASE; THROMBIN; UROKINASE;

DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; NEWBORN; NEWBORN SEPSIS; PREMATURITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TISSUE PERFUSION; TREATMENT OUTCOME;

EID: 0033427292     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994961     Document Type: Review

References (45)

1. Bone RC. Sepsis and its complications: The clinical problem. Crit Care Med 1994;22:S8-S11
2. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activator after administration of endotoxin to normal human subjects. N Engl J Med 990;320: 1165-1171
3. Hathaway WE, Mull MM, Pechet GS. Dissiminated intravascular coagulation in the newborn. Pediatrics 1969;43:233-238
4. Suffredini AF, Fromm RL, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-287
5. DeLa Cadena RA, Majluf-Cruz A, Stadnicki A, et al. Activation of the contact and fibrinolytic system after intravenous administration of endotoxin to normal human volunteers: Correlation with the cytokine profile. Immunopharmacol 1996;33:231-237
6. Massignon D, Lepape A, Bienvenu J, Barbier Y, Boileau C, Coeur P. Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state. Haemostasis 1994;24:36-48
7. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996;75: 224-228
8. Lao TT, Yin JA, Yuen PM. Coagulation and anticoagulation systems in newborns - correlation with their mothers at delivery. Lower levels of anticoagulants and fibrinolytic activity in the newborn. Gynecol Obstet Invest 1990;29:181-184
9. Caraco MD, Blanchette VS, Dean JA, et al. The platelet function analyser (PFA 100™) a novel in vitro system for evaluation of primary haemostasis in children. Br J Haematol 1998;101:70-73
10. Roman J, Velasco F, Fernadez F, et al. Protein C, protein S and C4b binding portein in neonatal severe infection and septic shock. J Perinat Med 1992;20:111-116
11. Suffredini AF. Current prospects for the treatment of clinical sepsis. Crit Care Med 1994;22:812-819
12. Dairaku M, Sueishi K, Tanaka K. Disseminated coagulation in newborn infants. Prevalence in autopsies and significance as a cause of death. Pathol Res Pract 1982;174:106-115
13. Andrew M, Peasr B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72:1651-1657
14. Lorente JA, Gracia Frade LJ, et al. Time course of hemostatic abnormalities during sepsis and its relation to outcome. Chest 1993;103:1536-1542
15. Leithauser B, Matthias FR, Nicolai U, Voss R. Haemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation? Intensive Care Med 1996;22: 631-636
16. Fijndvandraat K, Derkx B, Peters M, et al. Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict a high mortality. Thromb Haemost 1995;73:15-20
17. Veldmann A, Escuriola Ettingshausen C, Fischer D, et al. Sepsis of the premature infant: Treatment with protein C concentrate. Intensive Care Med 1998;24(suppl. 1):S179. Abstract
18. Schmidt BK, Muraji T, Zipursky A. Low antithrombin III in neonatal shock: DIC or non-specific protein depletion. Eur J Pediatr 1986;145:500-503
19. Schmidt B, Vegh P, Johnston M, Andrew M, Weitz J. Do coagulation tests detect increased generation of thrombin and plasmin in sick newborn infants? Thromb Haemost 1993;69:418-421
20. Coleman RW, Robboy SJ, Minna JD. DIC: A reappraisal. Annu Rev Med 1979;30:359-364
21. Corrigan JJ Jr. Heparin therapy in bacterial septicaemia. J Pediatr 1977;91:695-699
22. Corrigan JJ Jr, Jordan CM, Bennett BB. DIC in septic shock: Report of three cases not treated with heparin. Am J Dis Child 1973;126:629-631
23. Haneberg B, Gutteberg TJ, Moe JP, et al. Heparin for infants and meningococcal septicemia. Results of a randomized therapeutic trial. NIPH Ann 1983;6:43-48
24. Kries R, Stannigel H, Göbel U. Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation. Eur J Pediatr 1985;144: 191-194
25. Vieira A, Berry L, Ofsu F, Andrew M. Heparin sensitivity and resistance in the neonate: An explanation: Thromb Res 1991;63: 85-98
26. Fourrier F, Chopin C, Huart J, Runge C, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104:882-888
27. Mammen EF, Miyakawa T, Philips TF, Assarvian GS, Brown JM, Murano G. Antithrombin III concentrates and experimental disseminated intravascular coagulation. Semin Thromb Hemost 1985;11:373-383
28. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure and disseminated intravascular coagulation. Chest 1992;101:816-823
29. Eisele B, Lamy M, Keinecke H-O, et al. Antithrombin III in patients with severe sepsis: A randomized placebo controlled double - blind multicenter trial plus a metaanalysis on all randomised placebo controlled double - blind trials with AT III in severe sepsis. Intensive Care Med 1988;24:663-672
30. Nowak Göttl U, Groll A, Kreuz W, et al. Behandlung der Verbrauchskoagulopathie mit Antithrombin III Konzentrat bei Kindern mit nachgewiesener Sepsis. Klin Pädiatr 1992;204: 134-140
31. Taylor FB, Chang A, Esmon CT. Protein C prevents the coagulopathic and lethal effects of Echerichia coli in the baboon. J Clin Invest 1987;79:918-925
32. Rivard GE, David M, Farrel C. Treatment of purpura fulminans in meningococcaemia with protein C concentrate. J Pediatr 1995;126:646-652
33. Smith OP, White B, Vaughan D, Claffey L, Lyons B, Casey W. Use of protein C concentrate, heparin, and haemodiafiltration in meningococcus induced purpura fulminans. Lancet 1997; 370:1590-1593
34. Rintala E, Seppälä O, Kotilainen P, Pettilä V, Rasi V. Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med 1998;26:965-968
35. Kreuz W, Veldmann A, Escuriola-Ettingshausen C, Schneider W, Beeg T. Protein-C concentrate for meningococcal purpura fulminans. Lancet 1998;351:986-987
36. Yasuhiro K, Kumiko A, Hirofumi T, Mamoru K, Akinobu F. Characteristic effects of activated human protein C on tissue thromboplastin induced disseminated intravascular coagulation in rabbits. Thromb Res 1994;76:353-362
37. Sakata Y, Curriden S, Lawrence D, Griffin JH, Luskutoff DJ. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases plasminogen activator inhibitor activity in endothelial cell condition medium. Blood 1985;65: 444-451
38. Bajzar L, Manuel R, Nesheim M. Purification and characterisation of TAFI, a thrombin activatable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-14484
39. Bajzar L, Nesheim M, Tracy P. The profibrinolytic effect of activated protein C in clots formed by plasma is TAFI dependent. Blood 1996;88:2093-2100
40. Zenz W, Muntean W, Gallistl S, et al. Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococcemia. Pediatrics 1995;96:144-148
41. Zenz W, Bodo Z, Zobel G, Fanconi S, Rettenbacher A. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med 1998;26:969-970
42. Veldmann A, Ehrenberg A, Jäger G, Escuriola Ettingshausen C, Schneider W, Kreuz W. Is recombinant tissue plasminogen activator an option in the treatment of purpura fulminans? Crit Care Med (in press)
43. Cugno M, Cicardi M, Botasso B, et al. Activation of the coagulation cascade in C1-INH-inhibitor deficiencies. Blood 1997;89: 3213-3218
44. Nürnberger W, Petrik K, Göbel G, Burdach S, Göbel U. Inhibition of the classical pathway of complement in capillary leakage syndrome. Intensive Care Med 1994;20(suppl 1):S2. (Abstract)
45. Vangerow B, Marx G, Leuwer M, Piepenbrock S, Rückoldt H. C1-Inhibitor-activity, fluid balance and 30 day mortality in septic patients. Intensiv-und Notfallmedizin 1997;34(suppl 1): 49. (Abstract)